See more : Kinatico Ltd (KYP.AX) Income Statement Analysis – Financial Results
Complete financial analysis of Quince Therapeutics, Inc. (QNCX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Quince Therapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- e-therapeutics plc (ETX.L) Income Statement Analysis – Financial Results
- IDW Media Holdings, Inc. (IDWM) Income Statement Analysis – Financial Results
- Rosier SA (ENGB.BR) Income Statement Analysis – Financial Results
- Next Fifteen Communications Group plc (NFC.L) Income Statement Analysis – Financial Results
- Systena Corporation (2317.T) Income Statement Analysis – Financial Results
Quince Therapeutics, Inc. (QNCX)
About Quince Therapeutics, Inc.
Quince Therapeutics, Inc., a biopharmaceutical company, focuses on advancing precision therapeutics for debilitating and rare diseases. The company has discovered a broad bone-targeting drug platform to precisely deliver small molecules, peptides, or large molecules directly to the site of bone fracture and disease. Its lead compound is NOV004, an anabolic peptide engineered to precisely target and concentrate at the bone fracture site The company was formerly known as Cortexyme, Inc. and changed its name to Quince Therapeutics, Inc. in August 2022. Quince Therapeutics, Inc. was incorporated in 2012 and is headquartered in South San Francisco, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 322.00K | 175.00K | 344.00K | 332.00K | 188.00K | 51.00K | 45.00K |
| Gross Profit | -322.00K | -175.00K | -344.00K | -332.00K | -188.00K | -51.00K | -45.00K |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 9.45M | 25.18M | 60.80M | 61.31M | 30.21M | 10.09M | 9.10M |
| General & Administrative | 17.70M | 26.01M | 29.52M | 17.59M | 8.95M | 2.03M | 1.27M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 17.70M | 26.01M | 29.52M | 17.59M | 8.95M | 2.03M | 1.27M |
| Other Expenses | 7.48M | -997.00K | -247.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 34.62M | 51.19M | 90.32M | 78.89M | 39.17M | 12.12M | 10.37M |
| Cost & Expenses | 34.62M | 51.19M | 90.32M | 78.89M | 39.17M | 12.12M | 10.37M |
| Interest Income | 3.48M | 1.07M | 620.00K | 2.04M | 2.19M | 806.00K | 0.00 |
| Interest Expense | 0.00 | 568.00K | 0.00 | 0.00 | 0.00 | 957.00K | 1.64M |
| Depreciation & Amortization | 322.00K | 175.00K | 344.00K | 332.00K | 188.00K | 51.00K | 45.00K |
| EBITDA | -31.26M | -52.02M | -89.97M | -78.56M | -38.98M | -12.07M | -10.33M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -34.62M | -52.02M | -90.32M | -78.89M | -39.17M | -12.12M | -10.37M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 3.04M | 71.00K | 373.00K | 2.04M | 2.19M | -357.00K | -1.87M |
| Income Before Tax | -31.58M | -51.94M | -89.95M | -76.85M | -36.98M | -12.48M | -12.24M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | -197.00K | -284.00K | -620.00K | 2.17M | -188.00K | 357.00K | 1.87M |
| Net Income | -31.39M | -51.66M | -89.33M | -76.85M | -36.79M | -12.48M | -12.24M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -0.84 | -1.54 | -3.01 | -2.63 | -1.93 | -0.58 | -0.57 |
| EPS Diluted | -0.84 | -1.54 | -3.01 | -2.63 | -1.93 | -0.58 | -0.57 |
| Weighted Avg Shares Out | 37.24M | 33.50M | 29.72M | 29.18M | 19.03M | 21.55M | 21.55M |
| Weighted Avg Shares Out (Dil) | 37.24M | 33.50M | 29.72M | 29.18M | 19.03M | 21.55M | 21.55M |
Insider Weekends: Director Of Accelerate Diagnostics Adds To His Stock
Insider buying decreased significantly last week. Notable Insider Buys: Accelerate Diagnostics, Inc., Keurig Dr Pepper Inc., Vishay Precision Group, Inc., Corte
David Lamond Acquires 49,125 Shares of Cortexyme, Inc. (NASDAQ:CRTX) Stock
Cortexyme, Inc. (NASDAQ:CRTX) Director David Lamond acquired 49,125 shares of Cortexyme stock in a transaction that occurred on Thursday, June 4th. The stock was acquired at an average cost of $41.73 per share, for a total transaction of $2,049,986.25. Following...
Insider Weekends: Moderna Executives Go On A Selling Spree
Insider buying decreased significantly last week. Notable Insider Buys: Mercury General Corporation, Cortexyme, Inc., New Mountain Finance Corporation, Berkshir
Cortexyme Announces First Quarter 2020 Financial Results and Provides Business Update
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Cortexyme, Inc. (Nasdaq: CRTX), a clinical stage biopharmaceutical company pioneering potential therapeutics for Alzheimer’s and other degenerative diseases, today announced financial results for the first quarter 2020 and provided an update on its business. “The current...
Cortexyme to Present at the BofA Securities 2020 Health Care Conference on May 13, 2020
Cortexyme, Inc. (Nasdaq: CRTX), a clinical stage biopharmaceutical company pioneering a novel disease-modifying therapeutic approach to treat what it
Summit Financial Group Reports First Quarter 2020 Results
MOOREFIELD, W.V., April 30, 2020 -- Summit Financial Group, Inc. (“Company” or “Summit”) (NASDAQ: SMMF) today reported first quarter 2020 net income of $4.51 million, or $0.35.
During Ramadan, our ritual of gathering won’t happen but our values of community remain
This year, we plan on holding our prayers at home as a family and focusing on the blessings of health and wellness despite social distancing.
Cortexyme, Inc. (NASDAQ:CRTX) Position Increased by Bank of New York Mellon Corp
Bank of New York Mellon Corp boosted its holdings in Cortexyme, Inc. (NASDAQ:CRTX) by 180.6% during the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 38,867 shares of the...
Cortexyme, Inc. (NASDAQ:CRTX) Short Interest Up 16.9% in March
Cortexyme, Inc. (NASDAQ:CRTX) saw a large growth in short interest during the month of March. As of March 31st, there was short interest totalling 1,630,000 shares, a growth of 16.9% from the March 15th total of 1,393,800 shares. Currently, 13.8%...
Analysts Offer Insights on Healthcare Companies: Elanco Animal Health (ELAN) and Cortexyme (CRTX)
Analysts have been eager to weigh in on the Healthcare sector with new ratings on Elanco Animal Health (ELAN) and Cortexyme (CRTX). Elanco Animal Health
Source: https://incomestatements.info
Category: Stock Reports